Literature DB >> 12574128

The C-terminal domain of pol II and a DRB-sensitive kinase are required for 3' processing of U2 snRNA.

Joanne E Medlin1, Patricia Uguen, Alice Taylor, David L Bentley, Shona Murphy.   

Abstract

The human snRNA genes transcribed by RNA polymerase II (e.g. U1 and U2) have a characteristic TATA-less promoter containing an essential proximal sequence element. Formation of the 3' end of these non-polyadenylated RNAs requires a specialized 3' box element whose function is promoter specific. Here we show that truncation of the C-terminal domain (CTD) of RNA polymerase II and treatment of cells with CTD kinase inhibitors, including DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole), causes a dramatic reduction in proper 3' end formation of U2 transcripts. Activation of 3' box recognition by the phosphorylated CTD would be consistent with the role of phospho-CTD in mRNA processing. CTD kinase inhibitors, however, have little effect on initiation or elongation of transcription of the U2 genes, whereas elongation of transcription of the beta-actin gene is severely affected. This result highlights differences in transcription of snRNA and mRNA genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574128      PMCID: PMC145437          DOI: 10.1093/emboj/cdg077

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  39 in total

1.  The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters.

Authors:  R Ratnasabapathy; M Sheldon; L Johal; N Hernandez
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

2.  Inhibitors of transcription such as 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit.

Authors:  M F Dubois; V T Nguyen; S Bellier; O Bensaude
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

Review 3.  Reversible phosphorylation of the C-terminal domain of RNA polymerase II.

Authors:  M E Dahmus
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

4.  The CDC2-related kinase PITALRE is the catalytic subunit of active multimeric protein complexes.

Authors:  J Garriga; X Mayol; X Graña
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

5.  A 7 bp mutation converts a human RNA polymerase II snRNA promoter into an RNA polymerase III promoter.

Authors:  S M Lobo; N Hernandez
Journal:  Cell       Date:  1989-07-14       Impact factor: 41.582

6.  A kinase-deficient transcription factor TFIIH is functional in basal and activated transcription.

Authors:  T P Mäkelä; J D Parvin; J Kim; L J Huber; P A Sharp; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

7.  RNA polymerase II C-terminal domain required for enhancer-driven transcription.

Authors:  H P Gerber; M Hagmann; K Seipel; O Georgiev; M A West; Y Litingtung; W Schaffner; J L Corden
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

8.  Requirement for TFIIH kinase activity in transcription by RNA polymerase II.

Authors:  S Akoulitchev; T P Mäkelä; R A Weinberg; D Reinberg
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

9.  Concerted evolution of the tandem array encoding primate U2 snRNA occurs in situ, without changing the cytological context of the RNU2 locus.

Authors:  T Pavelitz; L Rusché; A G Matera; J M Scharf; A M Weiner
Journal:  EMBO J       Date:  1995-01-03       Impact factor: 11.598

10.  Common and unique transcription factor requirements of human U1 and U6 snRNA genes.

Authors:  J Bernués; K A Simmen; J D Lewis; S I Gunderson; M Polycarpou-Schwarz; V Moncollin; J M Egly; I W Mattaj
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  46 in total

1.  3'-box-dependent processing of human pre-U1 snRNA requires a combination of RNA and protein co-factors.

Authors:  Patricia Uguen; Shona Murphy
Journal:  Nucleic Acids Res       Date:  2004-06-01       Impact factor: 16.971

2.  RNA polymerase II carboxy-terminal domain phosphorylation is required for cotranscriptional pre-mRNA splicing and 3'-end formation.

Authors:  Gregory Bird; Diego A R Zorio; David L Bentley
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 3.  The Cajal body: a meeting place for spliceosomal snRNPs in the nuclear maze.

Authors:  David Stanek; Karla M Neugebauer
Journal:  Chromosoma       Date:  2006-03-31       Impact factor: 4.316

Review 4.  Formation of the 3' end of histone mRNA: getting closer to the end.

Authors:  Zbigniew Dominski; William F Marzluff
Journal:  Gene       Date:  2007-05-04       Impact factor: 3.688

5.  cis- and trans-Acting determinants of transcription termination by yeast RNA polymerase II.

Authors:  Eric J Steinmetz; Sarah B H Ng; Joseph P Cloute; David A Brow
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

6.  Chromatin structure is implicated in "late" elongation checkpoints on the U2 snRNA and beta-actin genes.

Authors:  Sylvain Egloff; Hadeel Al-Rawaf; Dawn O'Reilly; Shona Murphy
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

7.  Transcription termination by nuclear RNA polymerases.

Authors:  Patricia Richard; James L Manley
Journal:  Genes Dev       Date:  2009-06-01       Impact factor: 11.361

8.  The 3' ends of human pre-snRNAs are produced by RNA polymerase II CTD-dependent RNA processing.

Authors:  Patricia Uguen; Shona Murphy
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

9.  Gene-Specific Control of tRNA Expression by RNA Polymerase II.

Authors:  Alan Gerber; Keiichi Ito; Chi-Shuen Chu; Robert G Roeder
Journal:  Mol Cell       Date:  2020-04-15       Impact factor: 17.970

10.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.